Article Versions Notes

Maity TK, Kim EY, Cultraro CM, Venugopalan A, Khare L, Poddutoori R, Marappan S, Syed SD, Telford WG, Samajdar S, et al. Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance. Cancers. 2023; 15(8):2263. https://doi.org/10.3390/cancers15082263

Maity, Tapan K., Eun Young Kim, Constance M. Cultraro, Abhilash Venugopalan, Leena Khare, Ramulu Poddutoori, Sivapriya Marappan, Samiulla D. Syed, William G. Telford, Susanta Samajdar, and et al. 2023. "Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance" Cancers 15, no. 8: 2263. https://doi.org/10.3390/cancers15082263

Maity, T. K., Kim, E. Y., Cultraro, C. M., Venugopalan, A., Khare, L., Poddutoori, R., Marappan, S., Syed, S. D., Telford, W. G., Samajdar, S., Ramachandra, M., & Guha, U. (2023). Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance. Cancers, 15(8), 2263. https://doi.org/10.3390/cancers15082263